{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:38:02Z","timestamp":1781829482280,"version":"3.54.5"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Background. There is a wide spectrum of treatments available for actinic keratosis (AK). Topical diclofenac sodium and imiquimod are two topical treatments, which are noninvasive, easily applied, well-tolerated and effective.<\/jats:p>\n               <jats:p>Aim. To compare the effects of topical 3% diclofenac sodium plus hyaluranon (DFS) gel, 5% imiquimod (IMQ) cream, and base cream (BC) in patients with AK.<\/jats:p>\n               <jats:p>Methods. In total, 61 patients, diagnosed clinically and histopathologically as having AK, were randomized into three treatment groups to receive topical treatment with either DFS (twice daily for 12 weeks), IMQ (twice per week for 16 weeks) or BC (twice daily for 12 weeks). Patients were evaluated clinically at 0, 4, 8, 12, 16, 20 and 24 weeks. Treatment efficacy was assessed by Total Thickness Score (TTS) and Patient Global Improvement Index (PGII).<\/jats:p>\n               <jats:p>Results. Complete clearance rates for DFS, IMQ and BC at the end of the treatment and at the end of the total follow-up period were 19.1%, 20% and 0%, and 14.3%, 45% and 0%, respectively. Although the average TTS value of the DFS group at week 24 was significantly higher than that of the IMQ group, the PGII values were not significantly different.<\/jats:p>\n               <jats:p>Conclusions. Although DFS and IMQ each had considerable efficacy in the treatment of AK, the efficacy of DFS seemed to decrease after cessation of treatment.<\/jats:p>","DOI":"10.1111\/j.1365-2230.2010.03999.x","type":"journal-article","created":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T17:21:20Z","timestamp":1300728080000},"page":"479-484","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses"],"prefix":"10.1093","volume":"36","author":[{"given":"S.","family":"Akarsu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dokuz Eylul University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e.","family":"Aktan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokuz Eylul University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Atahan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokuz Eylul University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokuz Eylul University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e.","family":"\u00d6zkan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dokuz Eylul University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"2023012703541121700_b1","first-page":"S1","article-title":"Actinic keratosis: sequelae and treatments. Recommendations from a consensus panel","volume":"55","author":"Berman","year":"2006","journal-title":"J Fam Pract"},{"key":"2023012703541121700_b2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"de Berker","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023012703541121700_b3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00128071-200405060-00004","article-title":"Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma)","volume":"5","author":"Lober","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"2023012703541121700_b4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/archderm.1997.03890460061007","article-title":"An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratosis","volume":"133","author":"Rivers","year":"1997","journal-title":"Arch Dermatol"},{"key":"2023012703541121700_b5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2340\/00015555-0213","article-title":"Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel","volume":"87","author":"Rivers","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"2023012703541121700_b6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-4632.2007.03060.x","article-title":"Topical diclofenac in the treatment of actinic keratoses","volume":"46","author":"Merk","year":"2007","journal-title":"Int J Dermatol"},{"key":"2023012703541121700_b7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluranon gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"2023012703541121700_b8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"2023012703541121700_b9","first-page":"401","article-title":"Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze)","volume":"3","author":"Nelson","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"2023012703541121700_b10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1440-0960.1997.tb01693.x","article-title":"Topical diclofenac\/hyaluronic acid gel in the treatment of solar keratoses","volume":"38","author":"McEwan","year":"1997","journal-title":"Australas J Dermatol"},{"key":"2023012703541121700_b11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2023012703541121700_b12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.jid.5700264","article-title":"Imiquimod for actinic keratosis: systematic review and meta-analysis","volume":"126","author":"Hadley","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2023012703541121700_b13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1067\/mjd.2002.126257","article-title":"Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open label trial","volume":"47","author":"Salasche","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2023012703541121700_b14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2023012703541121700_b15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00042728-200506000-00008","article-title":"Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5%","volume":"31","author":"Lee","year":"2005","journal-title":"Dermatol Surg"},{"key":"2023012703541121700_b16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"key":"2023012703541121700_b17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.0366-077X.2003.05629.x","article-title":"Summary of actinic keratosis studies with imiquimod 5% cream","volume":"149","author":"Tran","year":"2003","journal-title":"Br J Dermatol"},{"key":"2023012703541121700_b18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023012703541121700_b19","first-page":"156","article-title":"Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp","volume":"5","author":"Smith","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"2023012703541121700_b20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/09546630701818870","article-title":"Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis","volume":"19","author":"Kose","year":"2008","journal-title":"J Dermatolog Treat"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2230.2010.03999.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/36\/5\/479\/46913198\/ced0479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/36\/5\/479\/46913198\/ced0479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T04:11:21Z","timestamp":1674792681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/36\/5\/479\/6622336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2230.2010.03999.x","relation":{},"ISSN":["1365-2230","0307-6938"],"issn-type":[{"value":"1365-2230","type":"electronic"},{"value":"0307-6938","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,7,1]]},"published":{"date-parts":[[2011,7,1]]}}}